18 May 2013
Keywords: GlaxoSmithKline, ChemoCentryx, Traficet-EN, Inflammatory bowel syndrome, Crohn's disease
Article | 12 January 2010
As part of a deal signed in 2006, UK drug giant GlaxoSmithKline has exercised its option to obtain an exclusive license ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.